• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疟原虫 Pf 型质体穿透素 X 的底物肽拟似物抑制剂具有很强的抗疟活性。

Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.

机构信息

Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Victoria, Australia.

Department of Medical Biology, University of Melbourne, Parkville, 3010, Victoria, Australia.

出版信息

ChemMedChem. 2022 Sep 16;17(18):e202200306. doi: 10.1002/cmdc.202200306. Epub 2022 Aug 18.

DOI:10.1002/cmdc.202200306
PMID:35906744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9804387/
Abstract

Plasmepsin X (PMX) is an aspartyl protease that processes proteins essential for Plasmodium parasites to invade and egress from host erythrocytes during the symptomatic asexual stage of malaria. PMX substrates possess a conserved cleavage region denoted by the consensus motif, SFhE (h=hydrophobic amino acid). Peptidomimetics reflecting the P -P positions of the consensus motif were designed and showed potent and selective inhibition of PMX. It was established that PMX prefers Phe in the P position, di-substitution at the β-carbon of the P moiety and a hydrophobic P group which was supported by modelling of the peptidomimetics in complex with PMX. The peptidomimetics were shown to arrest asexual P. falciparum parasites at the schizont stage by impairing PMX substrate processing. Overall, the peptidomimetics described will assist in further understanding PMX substrate specificity and have the potential to act as a template for future antimalarial design.

摘要

裂殖体蛋白 X(PMX)是一种天冬氨酸蛋白酶,在疟疾有症状的无性生殖阶段,它能处理疟原虫侵入和逸出宿主红细胞所必需的蛋白质。PMX 的底物具有一个保守的切割区域,由共识基序 SFhE(h=疏水性氨基酸)表示。反映共识基序 P-P 位置的肽模拟物被设计出来,并表现出对 PMX 的有效和选择性抑制。研究结果表明,PMX 偏爱 P 位的苯丙氨酸,P 部分的β-碳上的二取代和疏水性 P 基团,这一结果得到了与 PMX 形成复合物的肽模拟物的建模支持。这些肽模拟物通过损害 PMX 底物的加工,使无性生殖的恶性疟原虫寄生虫停滞在裂殖体阶段。总的来说,所描述的肽模拟物将有助于进一步了解 PMX 底物特异性,并有可能作为未来抗疟药物设计的模板。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/7d4d64116a2a/CMDC-17-0-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/2ab5540c42ef/CMDC-17-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/677b4b5e4064/CMDC-17-0-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/37b98af4b3f3/CMDC-17-0-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/a36583f30621/CMDC-17-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/9ef56efcd90c/CMDC-17-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/a285556a8f0a/CMDC-17-0-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/4db601724eed/CMDC-17-0-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/7d4d64116a2a/CMDC-17-0-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/2ab5540c42ef/CMDC-17-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/677b4b5e4064/CMDC-17-0-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/37b98af4b3f3/CMDC-17-0-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/a36583f30621/CMDC-17-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/9ef56efcd90c/CMDC-17-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/a285556a8f0a/CMDC-17-0-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/4db601724eed/CMDC-17-0-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d75c/9804387/7d4d64116a2a/CMDC-17-0-g009.jpg

相似文献

1
Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.疟原虫 Pf 型质体穿透素 X 的底物肽拟似物抑制剂具有很强的抗疟活性。
ChemMedChem. 2022 Sep 16;17(18):e202200306. doi: 10.1002/cmdc.202200306. Epub 2022 Aug 18.
2
Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P position of PEXEL peptidomimetics.通过修饰 PEXEL 肽模拟物的 P 位增强疟原虫蛋白酶 V 抑制剂的抗疟活性。
Eur J Med Chem. 2018 Jun 25;154:182-198. doi: 10.1016/j.ejmech.2018.05.022. Epub 2018 May 18.
3
Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent and Antimalarial Activity.大环肽拟肽原虫 X 抑制剂具有强效抗疟活性。
J Med Chem. 2023 Aug 10;66(15):10658-10680. doi: 10.1021/acs.jmedchem.3c00812. Epub 2023 Jul 28.
4
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of .发现并表征强效、有效、可口服的抗疟原虫裂殖体蛋白 X 抑制剂和. 的临床前安全性评估
J Med Chem. 2022 Oct 27;65(20):14121-14143. doi: 10.1021/acs.jmedchem.2c01336. Epub 2022 Oct 10.
5
Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.深入了解修饰的司他汀核心的肽模拟抑制剂对恶性疟原虫 Plasmodium falciparum 中裂殖体蛋白酶 II 与人类组织蛋白酶 D 的选择性。
Chem Biol Drug Des. 2012 Apr;79(4):411-30. doi: 10.1111/j.1747-0285.2011.01276.x.
6
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.裂殖体疟原虫和 vivax 中裂殖体蛋白酶 IX 和 X 抑制的药物选择性基础。
Structure. 2022 Jul 7;30(7):947-961.e6. doi: 10.1016/j.str.2022.03.018. Epub 2022 Apr 22.
7
Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.利用主要区域实现对疟原虫必需蛋白酶——疟原虫天冬氨酸蛋白酶V的皮摩尔级抑制。
PLoS One. 2015 Nov 13;10(11):e0142509. doi: 10.1371/journal.pone.0142509. eCollection 2015.
8
Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).疟原虫属蛋白酶抑制剂在抗疟药物研发中的应用:药物化学和靶点确证(2000 年至今)。
J Med Chem. 2020 May 14;63(9):4445-4467. doi: 10.1021/acs.jmedchem.9b01622. Epub 2020 Jan 23.
9
The malaria parasite egress protease SUB1 is activated through precise, plasmepsin X-mediated cleavage of the SUB1 prodomain.疟原虫外排蛋白酶 SUB1 通过精准的、依赖于 plasmepsin X 的 SUB1 前导肽切割而被激活。
Biochim Biophys Acta Gen Subj. 2024 Sep;1868(9):130665. doi: 10.1016/j.bbagen.2024.130665. Epub 2024 Jul 3.
10
Azole-based non-peptidomimetic plasmepsin inhibitors.基于唑的非肽类裂殖体蛋白酶抑制剂。
Arch Pharm (Weinheim). 2018 Sep;351(9):e1800151. doi: 10.1002/ardp.201800151. Epub 2018 Jul 31.

引用本文的文献

1
Structure-activity analysis of imino-pyrimidinone-fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors.亚氨基嘧啶酮稠合吡咯烷的构效关系分析有助于双血浆蛋白酶V和血浆蛋白酶X抑制剂的开发。
FEBS J. 2025 Jun;292(11):2843-2864. doi: 10.1111/febs.70038. Epub 2025 Mar 4.
2
Rapid Synthesis of anti-1,3-Diamino-4-phenylbutan-2-ol Building Blocks via a Three-Component Oxyhomologation and a Two-Component Reducing System.通过三组分氧同系化和双组分还原体系快速合成抗1,3 - 二氨基 - 4 - 苯基丁 - 2 - 醇结构单元
ChemistryOpen. 2025 Feb;14(2):e202400279. doi: 10.1002/open.202400279. Epub 2024 Oct 30.
3

本文引用的文献

1
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.裂殖体疟原虫和 vivax 中裂殖体蛋白酶 IX 和 X 抑制的药物选择性基础。
Structure. 2022 Jul 7;30(7):947-961.e6. doi: 10.1016/j.str.2022.03.018. Epub 2022 Apr 22.
2
Prioritization of Molecular Targets for Antimalarial Drug Discovery.抗疟药物发现中分子靶标的优先级排序。
ACS Infect Dis. 2021 Oct 8;7(10):2764-2776. doi: 10.1021/acsinfecdis.1c00322. Epub 2021 Sep 15.
3
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.
Towards next-generation treatment options to combat Plasmodium falciparum malaria.
迈向对抗恶性疟原虫疟疾的下一代治疗方案。
Nat Rev Microbiol. 2025 Mar;23(3):178-191. doi: 10.1038/s41579-024-01099-x. Epub 2024 Oct 4.
4
Chemo-proteomics in antimalarial target identification and engagement.抗疟药物靶标鉴定和结合的化学生物组学。
Med Res Rev. 2023 Nov;43(6):2303-2351. doi: 10.1002/med.21975. Epub 2023 May 26.
5
Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau.比热戈斯群岛人群间疟原虫的种群动态和耐药突变。
Sci Rep. 2023 Apr 18;13(1):6311. doi: 10.1038/s41598-023-33176-1.
6
7--Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome Complex.7--具有强抗疟活性的取代-3-噁二唑喹诺酮类化合物靶向细胞色素复合物。
ACS Infect Dis. 2023 Mar 10;9(3):668-691. doi: 10.1021/acsinfecdis.2c00607. Epub 2023 Feb 28.
7
Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.优化 2,3-二氢喹唑啉-4-甲酰胺类化合物作为抗疟原虫 PfATP4 的靶点。
J Med Chem. 2023 Mar 9;66(5):3540-3565. doi: 10.1021/acs.jmedchem.2c02092. Epub 2023 Feb 22.
优化具有中等至缓慢红细胞期活性的 2-(N-苯甲酰胺)三唑并嘧啶类抗疟药。
Bioorg Chem. 2021 Oct;115:105244. doi: 10.1016/j.bioorg.2021.105244. Epub 2021 Aug 8.
4
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.卢旺达青蒿素耐药恶性疟原虫kelch13 R561H 突变体寄生虫的体外出现和克隆扩增。
Nat Med. 2020 Oct;26(10):1602-1608. doi: 10.1038/s41591-020-1005-2. Epub 2020 Aug 3.
5
Malaria parasite plasmepsins: More than just plain old degradative pepsins.疟原虫原浆朊酶:不只是普通的古老降解胃蛋白酶。
J Biol Chem. 2020 Jun 19;295(25):8425-8441. doi: 10.1074/jbc.REV120.009309. Epub 2020 May 4.
6
Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.双重靶向疟原虫蛋白酶的抗疟药物破坏疟原虫生命周期的多个阶段。
Cell Host Microbe. 2020 Apr 8;27(4):642-658.e12. doi: 10.1016/j.chom.2020.02.005. Epub 2020 Feb 27.
7
Assessment of Biological Role and Insight into Druggability of the Protease Plasmepsin V.评估蛋白酶 Plasmepsin V 的生物学作用及可成药性研究。
ACS Infect Dis. 2020 Apr 10;6(4):738-746. doi: 10.1021/acsinfecdis.9b00460. Epub 2020 Feb 27.
8
Inhibition of Plasmepsin V Activity Blocks Plasmodium falciparum Gametocytogenesis and Transmission to Mosquitoes.抑制疟原虫裂殖子 V 活性可阻断疟原虫配子体形成和向蚊子传播。
Cell Rep. 2019 Dec 17;29(12):3796-3806.e4. doi: 10.1016/j.celrep.2019.11.073.
9
The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.现代抗疟药物的发现和临床推进的发展过程。
J Med Chem. 2019 Dec 12;62(23):10526-10562. doi: 10.1021/acs.jmedchem.9b00761. Epub 2019 Aug 20.
10
Evaluation of 4-Amino 2-Anilinoquinazolines against and Other Apicomplexan Parasites and in a Humanized NOD- IL2Rγ Mouse Model of Malaria.评估 4-氨基-2-苯胺基喹唑啉类化合物对 和其他顶复门寄生虫的作用 以及在疟疾人源化 NOD-IL2Rγ 小鼠模型中的作用。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.01804-18. Print 2019 Mar.